Maxygen, Inc., founded in 1997 and headquartered in Redwood City, CA, was a biopharmaceutical company focused on developing protein pharmaceuticals for the treatment of serious medical conditions. The company's core mission was to leverage its proprietary technologies to create innovative therapies that address unmet medical needs. Maxygen operated primarily within the United States and was publicly traded on the NASDAQ under the ticker symbol MAXY.
Notable figures associated with Maxygen include key leaders such as Russell Howard. The company achieved significant milestones in the biopharmaceutical industry before ceasing operations in 2013. During its active years, Maxygen's innovative approach to protein pharmaceuticals had a notable impact on the field, contributing to advancements in treatments for various diseases. Despite its eventual closure, Maxygen's legacy continues to influence biopharmaceutical research and development.